Dear ACoP2024 participants, We gladly invite you to our one-and-a-half day course in which we will discuss the importance of understanding the pharmacology of monoclonal antibodies (mAbs) to make the right decisions in target-mediated drug disposition (TMDD) model development.
If you want to learn more on; 1) the relevance of mechanistic modelling for mAbs, 2) the considerations with regards to scaling the model for first in human (FIH) approaches, and 3) what TMDD models are, what approximations may be applicable and how to use these models for (non-)clinical data. LAP&P's interactive course will be held on Thursday the 14th and Friday the 15th of November 2024 in Phoenix Arizona. After a short introduction, we will directly dive into a hands-on session, in which the participants work in small groups on TMDD modelling challenges using a nlmixr2 within a shinyMixR workflow. Find more information for the course on LAP&P course | LAPP<https://lapp.nl/lapp-course/> or register via the ACOP website (ACoP 2024 (eventscribe.net)<https://acop2024.eventscribe.net/index.asp>). For questions, feel free to reach out to us. Hope to see you there! Tamara van Steeg Tamara van Steeg, PhD Principal Consultant, Director of Research LAP&P Consultants Archimedesweg 31, 2333 CM Leiden The Netherlands Web: www.lapp.nl<http://www.lapp.nl/>
